- Home
- TOPS vs ASBP Comparison
TOPS vs ASBP Comparison
Compare TOPS & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- ASBP
- Stock Information
- Founded
- TOPS 2000
- ASBP 2021
- Country
- TOPS Greece
- ASBP United States
- Employees
- TOPS N/A
- ASBP N/A
- Industry
- TOPS Marine Transportation
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- ASBP Health Care
- Exchange
- TOPS Nasdaq
- ASBP Nasdaq
- Market Cap
- TOPS 26.6M
- ASBP 26.6M
- IPO Year
- TOPS 2004
- ASBP N/A
- Fundamental
- Price
- TOPS $5.82
- ASBP $0.52
- Analyst Decision
- TOPS
- ASBP
- Analyst Count
- TOPS 0
- ASBP 0
- Target Price
- TOPS N/A
- ASBP N/A
- AVG Volume (30 Days)
- TOPS 9.3K
- ASBP 191.2K
- Earning Date
- TOPS 04-29-2025
- ASBP 05-24-2025
- Dividend Yield
- TOPS N/A
- ASBP N/A
- EPS Growth
- TOPS N/A
- ASBP N/A
- EPS
- TOPS 1.09
- ASBP N/A
- Revenue
- TOPS $86,127,000.00
- ASBP N/A
- Revenue This Year
- TOPS $9.90
- ASBP N/A
- Revenue Next Year
- TOPS N/A
- ASBP N/A
- P/E Ratio
- TOPS $5.21
- ASBP N/A
- Revenue Growth
- TOPS 3.83
- ASBP N/A
- 52 Week Low
- TOPS $5.30
- ASBP $0.40
- 52 Week High
- TOPS $14.24
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- TOPS 46.00
- ASBP N/A
- Support Level
- TOPS $5.60
- ASBP N/A
- Resistance Level
- TOPS $5.85
- ASBP N/A
- Average True Range (ATR)
- TOPS 0.27
- ASBP 0.00
- MACD
- TOPS -0.01
- ASBP 0.00
- Stochastic Oscillator
- TOPS 39.64
- ASBP 0.00
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The company focuses on the transportation of petroleum products (clean and dirty) and bulk liquid chemicals. The Company is an international provider of worldwide oil, petroleum products and chemical transportation services. It generates revenue from the Time Charter agreements.
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tract.